Dr. GPCR and Eurofins Discovery Formed Drug Partnership
The alliance combines a global GPCR research network with integrated drug discovery and screening services.
Updated on Oct. 5, 2026 in Biotech
Dr. GPCR and Eurofins Discovery have announced a strategic partnership to accelerate G protein-coupled receptor (GPCR) drug development. The collaboration integrates end-to-end discovery services with a global research community.
Why it matters
The partnership aims to streamline the drug discovery pipeline by providing scientific context for experiment design and data interpretation. By consolidating stages from target identification to regulatory potency testing, the deal seeks to increase the efficiency of development.
The partnership leverages a combined 30 years of GPCR experience and 20 years of integrated drug discovery. Eurofins Discovery contributes a portfolio of over 2,750 assays to support the discovery process.
The players
Dr. GPCR
A global professional community focused on G protein-coupled receptor research and networking.
Eurofins Discovery
A provider of specialized drug discovery services including assay development and receptor characterization.
The details
This partnership connects Eurofins Discovery's established drug discovery capabilities—including compound characterization, assay development, and receptor deorphanization (the process of identifying the natural ligand for a receptor of unknown function)—with the Dr. GPCR research network. By integrating these services, research teams can manage workflows from target identification through lead optimization and final regulatory potency testing. The platform operates across multiple therapeutic areas, specifically metabolic disease, oncology, immunology, and CNS (central nervous system) disorders.
Timeline
October 5, 2026: The strategic partnership was formally announced.
Over the coming year: The community will receive information regarding Eurofins Discovery services.
The Tech Race
This partnership follows the industry trend of consolidating fragmented discovery services within the GPCR research landscape. It aims to compete by offering a singular, integrated provider for the entire lifecycle of receptor-targeted drug development.
Researchers within the Dr. GPCR community will gain direct access to Eurofins Discovery's screening infrastructure and service team over the next year. This integration potentially reduces the administrative and technical overhead for laboratories moving leads through to regulatory testing.
The takeaway
The partnership marks a shift toward unified, end-to-end support for researchers working on G protein-coupled receptors. Observers should track the release of new service documentation over the coming year to see how this impacts individual lab research timelines.
Further reading
Explore broader trends in Biotech to understand how research networks are integrating with commercial service providers.
Source note: This article includes information reported by News-Medical.
